Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 32 Show results per page	View Search Criteria \| Help With Results


1.		PharmacoEconomic Assessment IRESSA® in the Treatment of Non–Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Active				20 and over				Other				9461700718 NCT00173524


2.		Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				D7913C00046 NCT00536107


3.		Study Of Zd1839 (Iressa™) Versus Methotrexate For Previously Treated Patients With Squamous Cell Carcinoma Of The Head And Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				ZD1839IL/0704 NCT00072878

Last Modified: 9/18/2008 First Published: 7/23/2004


4.		Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1302 E1302, NCT00088907


5.		Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				SCRI UNKPRI 12 IRUSIRES0215, CPTAIV-0020-417, B9E-US-X423, NCT00193596

Last Modified: 4/17/2008 First Published: 7/7/2006


6.		Phase III Randomized Study of BCG With Versus Without Gefitinib in Patients With High-Risk Superficial Transitional Cell Carcinoma of the Bladder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CAN-NCIC-BL11 NCT00352079, BL11

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Natural history/Epidemiology, Treatment				Active				18 and over				Pharmaceutical / Industry				1839IL/0555 D7913L00008, NCT00357734

Last Modified: 8/10/2006 First Published: 6/23/2004


8.		Phase I/II Study of Gefitinib, Trastuzumab (Herceptin®), and Docetaxel in Patients With HER2/neu-Overexpressing Metastatic Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CHNMC-03049 ZENECA-1839US/0274, ZENECA-IRUSIRES0012, NCT00086957

Last Modified: 10/19/2006 First Published: 10/25/2004


9.		Phase I/II Study of Gefitinib and Everolimus in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MSKCC-04033 NCT00096486

Last Modified: 9/11/2008 First Published: 11/22/2004


10.		Phase I/II Study of Gefitinib and Sirolimus in Patients With Recurrent or Refractory Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UCLA-0407057-01 ZENECA-IRUSIRES0281, NCT00098462

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute